Background: Etoposide (E) at 100 mg/m combined with Cisplatin (P) at 20 mg/m represents an induction 2-day regimen embedded in our clinical practice for patients with advanced GCT or TN at high risk of early death. We evaluated 24/7 Em-EP administration to a combined GCT-TN cohort at our Emergency Cancer Treatment Centre (ECTC) to determine its efficacy within the acute setting.
Methods: Patients who received Em-EP during a five-year interval were identified from electronic databases at Imperial College Healthcare NHS Trust.